Erik de Clercq
Director/Miembro de la Junta en FermaVir Pharmaceuticals LLC .
Perfil
Erik De Clercq has been a Director of FermaVir Pharmaceuticals, Inc. since August 16, 2005 and FermaVir Research, Inc. since March, 2005.
He has been working with Rega Institute in Leuven since 1977.
Dr. De Clercq is a Professor of the Medical School at Leuven University, Leuven, Belgium.
He is Chairman and a Director of the Rega Institute and the Rega Foundation and Chairman of the Department of Microbiology and Immunology at Leuven University.
Cargos activos de Erik de Clercq
Empresas | Cargo | Inicio |
---|---|---|
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Director/Miembro de la Junta | 16/08/2005 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Erik de Clercq